About Nipro Corporation
Nipro Corporation is a company based in Osaka (Japan) founded in 1954. The company has 39,170 employees as of March 31, 2024. Nipro Corporation has completed 2 acquisitions, including Home Diagnostics and Infraredx. Nipro Corporation offers products and services including Medical Devices and Regenerative Medicine.
- Headquarter Osaka, Japan
- Employees 39170 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nipro Corporation
-
Annual Revenue
$4.31 B (USD)9.85as on Mar 31, 2025
-
Net Profit
$34.2 M (USD)-53.97as on Mar 31, 2025
-
EBITDA
$617.34 M (USD)13.59as on Mar 31, 2025
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
39170
as on Mar 31, 2024
-
Investments & Acquisitions
Home Diagnostics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nipro Corporation
Nipro Corporation is a publicly listed company on the TSE with ticker symbol 8086 in Japan, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nipro Corporation
Nipro Corporation offers a comprehensive portfolio of products and services, including Medical Devices and Regenerative Medicine.
Medical devices including dialyzers and syringes are manufactured to respond to medical site needs.
Regenerative medical products are developed and supplied to address treatments for conditions like spinal injuries.
People of Nipro Corporation
Unlock access to complete
Funding Insights of Nipro Corporation
Detailed funding history for Nipro Corporation
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nipro Corporation
Nipro Corporation has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Home Diagnostics and Infraredx.
Investment portfolio details for Nipro Corporation
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Coronary imaging and plaque detection system
|
Locked | Locked | 1998 | Locked | |
|
Home blood glucose monitoring systems are developed and marketed.
|
Locked | Locked | 1985 | Locked |
Complete acquisition details for Nipro Corporation
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Nipro Corporation
Detailed financials for Nipro Corporation
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nipro Corporation Comparisons
Peer comparison for Nipro Corporation
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nipro Corporation
Detailed competitors of Nipro Corporation
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nipro Corporation
Complete news archive for Nipro Corporation
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nipro Corporation
Nipro Corporation was founded in 1954.
Nipro Corporation is headquartered in Osaka, Japan. It is registered at Osaka, Osaka Prefecture, Japan.
As of Mar 31, 2024, the latest employee count at Nipro Corporation is 39,170.
Annual revenue of Nipro Corporation is $4.31B as on Mar 31, 2025.
Manufacturer of medical devices, pharmaceuticals, and regenerative medicine products. The company develops and manufactures a diverse portfolio of products, including dialysis equipment, various medical instruments, and a range of pharmaceuticals. A significant portion of their business focuses on regenerative medicine, offering products contributing to advancements in this field. Their operations encompass research and development, manufacturing, and distribution.
Nipro Corporation offers Medical Devices and Regenerative Medicine.
Yes, Nipro Corporation is publicly traded on TSE under the ticker symbol 8086.
Nipro Corporation has made 2 acquisitions, including Home Diagnostics, and Infraredx.
The ticker symbol of Nipro Corporation is 8086 on TSE.